154 related articles for article (PubMed ID: 38451530)
1. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Tsukita Y; Tozuka T; Kushiro K; Hosokawa S; Sumi T; Uematsu M; Honjo O; Yamaguchi O; Asao T; Sugisaka J; Saito G; Shiihara J; Morita R; Katakura S; Yasuda T; Hisakane K; Miyauchi E; Morita S; Kobayashi K; Asahina H
JAMA Oncol; 2024 Apr; 10(4):439-447. PubMed ID: 38451530
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
5. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Takei S; Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
Front Immunol; 2024; 15():1348034. PubMed ID: 38464519
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
15. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
[TBL] [Abstract][Full Text] [Related]
17. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
20. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
